1-11 of 11
Gabriel Marquez
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Treatment cost per AE symptom-free day of asciminib and second-generation tyrosine kinase inhibitors in newly diagnosed patients with chronic myeloid leukemia

Free
Jennifer Vaughn, Nadine Zawadzki, Caroline Hardy, Gabriel Marquez, Gopi Madhav Bommidi, Poornima Sachin Dhobe, Sai Vasmi Gedala, Islam Mohamad Sadek, Jason Shafrin, David Wei
Journal: Blood
Blood (2025) 146 (Supplement 1): 2835.
https://doi.org/10.1182/blood-2025-2835
Published: 2025
Journal Articles

Real-world treatment patterns, outcomes, and unmet needs in patients with ph+ ALL receiving tyrosine kinase inhibitors in the United States: Emerging trends and the role of asciminib-based combinations

Free
Marlise Luskin, Andrea Damon, Emily McGovern, Dominick Latremouille-Viau, Annie Guerin, Carmine Rossi, Fredrick Kinkhead, Gabriel Marquez, David Wei, Islam Mohamad Sadek, Elias Jabbour
Journal: Blood
Blood (2025) 146 (Supplement 1): 5097.
https://doi.org/10.1182/blood-2025-5097
Published: 2025
Journal Articles

Indirect treatment comparison (ITC) of asciminib and dasatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP)

Free
Onyee Chan, Gabriel Marquez, Valentine Laizet, Rob Mingxin Liu, Gabriela Friedrich, Katerina Papadimitropoulou, Isabelle Lundqvist, Shaun Walsh, Emily McGovern, Islam Mohamad Sadek, David Wei
Journal: Blood
Blood (2025) 146 (Supplement 1): 4611.
https://doi.org/10.1182/blood-2025-4611
Published: 2025
Journal Articles

The humanistic burden of patients with chronic myeloid leukemia (CML) treated with first line (1L) tyrosine kinase inhibitors (TKIs)

Free
Kelly Schoenbeck, Joan Clements, Karen Demairo, David Wei, Nisha Hazra, Cristina Constantinescu, Yan Meng, Dominick Latremouille-Viau, Gabriel Marquez, Daisy Yang, Andrea Damon, Islam Mohamad Sadek, Annie Guerin, Kathryn Flynn
Journal: Blood
Blood (2025) 146 (Supplement 1): 6388.
https://doi.org/10.1182/blood-2025-6388
Published: 2025
Journal Articles

Real-world analysis of asciminib as first-line therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A chart review Study in the United States

Free
Ehab Atallah, Islam Mohamad Sadek, Emily McGovern, Dominick Latremouille-Viau, Carmine Rossi, Remi Bellefleur, Gabriel Marquez, Annie Guerin, Daisy Yang, David Wei
Journal: Blood
Blood (2025) 146 (Supplement 1): 8178.
https://doi.org/10.1182/blood-2025-8178
Published: 2025
Journal Articles

A comparison of real-world outcomes of asciminib versus ATP-competitive tyrosine kinase inhibitors as second-line treatment in patients with chronic myeloid leukemia in chronic phase

Free
Ehab Atallah, Islam Mohamad Sadek, Emily McGovern, Dominick Latremouille-Viau, Carmine Rossi, Remi Bellefleur, Nathan Gobeil, Gabriel Marquez, Annie Guerin, Daisy Yang, David Wei
Journal: Blood
Blood (2025) 146 (Supplement 1): 724.
https://doi.org/10.1182/blood-2025-724
Published: 2025
Journal Articles

Improved long-term tolerability with asciminib (ASC) vs investigator-selected (IS) tyrosine kinase inhibitors (TKIs) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Week 96 exploratory analysis of the phase 3 ASC4FIRST trial

Free
Timothy Hughes, Jorge Cortes, Jennifer Vaughn, Kathryn Flynn, Naoto Takahashi, Ghayas Issa, Felice Bombaci, Jianxiang Wang, Dong-Wook Kim, Dennis Kim, Jiri Mayer, Yeow Tee Goh, Philipp le Coutre, Inho Kim, Gabriel Etienne, Rajendra Jinwal, Andrea Damon, David Wei, Gabriel Marquez, Ennan Gu, Gopi Madhav Bommidi, Andreas Hochhaus, Richard Larson
Journal: Blood
Blood (2025) 146 (Supplement 1): 5549.
https://doi.org/10.1182/blood-2025-5549
Published: 2025
Journal Articles

ASC4REAL: Efficacy and Tolerability Comparison between Ascembl Study, a Phase 3 Randomized Clinical Trial (RCT), and Consolidated Real-World (RW) Evidence with Asciminib in CML Patients Beyond 2 TKIs

Free
Anchit Khanna, Hannah Small, Dhamend Lutchman, Rafael Erlich, Gabriel Marquez, Daisy Yang, Kejal Jadhav
Journal: Blood
Blood (2024) 144 (Supplement 1): 4527.
https://doi.org/10.1182/blood-2024-201022
Published: 2024
Journal Articles

A Phase I Trial of CC-486, Lenalidomide, Obinutuzumab in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Free
Gabriel Marquez-Arreguin, Tamer Othman, Naseem S. Esteghamat, Mehrdad Abedi, Francisco Andres Socola, Joseph M Tuscano
Journal: Blood
Blood (2024) 144 (Supplement 1): 6317.
https://doi.org/10.1182/blood-2024-209452
Published: 2024
Journal Articles

Gut-associated lymphoid tissue–primed CD4 + T cells display CCR9-dependent and -independent homing to the small intestine

Free
Hanna Stenstad, Anna Ericsson, Bengt Johansson-Lindbom, Marcus Svensson, Jan Marsal, Matthias Mack, Dominic Picarella, Dulce Soler, Gabriel Marquez, Mike Briskin, William W. Agace
Journal: Blood
Blood (2006) 107 (9): 3447–3454.
https://doi.org/10.1182/blood-2005-07-2860
Published: 2006
Journal Articles

CC chemokine ligand 20 partially controls adhesion of naive B cells to activated endothelial cells under shear stress

Free
Brief Report
Anja Meissner, Olaf Zilles, Rosa Varona, Katrin Jozefowski, Uwe Ritter, Gabriel Marquez, Rupert Hallmann, Heinrich Körner
Journal: Blood
Blood (2003) 102 (8): 2724–2727.
https://doi.org/10.1182/blood-2003-01-0007
Published: 2003